The Korean Deal currently produces ZERO revenue so I'd say your assumption is incorrect
I think you have totally missed the CAUSE of the issue (the process economic viability). No financing for Lancaster, no financing for Fulton, no revenues from SucreSource, no licensing revenues to anyone in the world who might want to operate with the Arkenol Process.
Do you suspect there might be a reason for that total lack of interest?????
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.